Citat:
Studien som tar med dessa 11/13 spekulerar i att de burit på tidigare asymptomatisk smitta och således hade ett befintligt försvar som tog hand om S1 innan det kom till detekterbara nivåer i serum. Jag läser, och ser ingenting nytt. Det är ju just detta som är problemet, att följande har visat sig inte stämma;
"Compare this, though, to what happens in vaccination. The injection is intramuscular, not into the bloodstream. That’s why a muscle like the deltoid is preferred, because it’s a good target of thicker muscle tissue without any easily hit veins or arteries at the site of injection. The big surface vein in that region is the cephalic vein, and it’s down along where the deltoid and pectoral muscles meet, not high up in the shoulder. In earlier animal model studies of mRNA vaccines, such administration was clearly preferred over a straight i.v. injection; the effects were much stronger. So the muscle cells around the injection are hit by the vaccine (whether mRNA-containing lipid nanoparticles or adenovirus vectors) while a good portion of the remaining dose is in the intercellular fluid and thus drains through the lymphatic system, not the bloodstream. That’s what you want, since the lymph nodes are a major site of immune response. The draining lymph nodes for the deltoid are going to be the deltoid/pectoral ones where those two muscles meet, and the larger axillary lymph nodes down in the armpit on that side."
Alla tycks dock inte få samma effekt, tex fann man spikproteinet i blodomloppet hos 11/13 vaccinerade kanadensiska sjuksköterskor - inte 13/13.
"Compare this, though, to what happens in vaccination. The injection is intramuscular, not into the bloodstream. That’s why a muscle like the deltoid is preferred, because it’s a good target of thicker muscle tissue without any easily hit veins or arteries at the site of injection. The big surface vein in that region is the cephalic vein, and it’s down along where the deltoid and pectoral muscles meet, not high up in the shoulder. In earlier animal model studies of mRNA vaccines, such administration was clearly preferred over a straight i.v. injection; the effects were much stronger. So the muscle cells around the injection are hit by the vaccine (whether mRNA-containing lipid nanoparticles or adenovirus vectors) while a good portion of the remaining dose is in the intercellular fluid and thus drains through the lymphatic system, not the bloodstream. That’s what you want, since the lymph nodes are a major site of immune response. The draining lymph nodes for the deltoid are going to be the deltoid/pectoral ones where those two muscles meet, and the larger axillary lymph nodes down in the armpit on that side."
Alla tycks dock inte få samma effekt, tex fann man spikproteinet i blodomloppet hos 11/13 vaccinerade kanadensiska sjuksköterskor - inte 13/13.
Men den risk som förknippas med detta verkar vara blodpropparna. Och det är ju en stark misstänkt, men väldigt ovanlig biverkan av Jansen- och AZ. För mRNA-vaccinen har den inte dykt upp öht.
Så vad är den verkliga risken med detta?
Så här kan det ju också tolkas
https://www.sciencedaily.com/releases/2021/05/210526185844.htm
Någonstans borde ju mängden även ha en relevans.
Troligtvis ett på tok förstorat fynd.